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ABSTRACT
Calretinin (CALB2) is a diagnostic marker for epithelioid mesothelioma. It is 
also a prognostic marker since patients with tumors expressing high calretinin levels 
have better overall survival. Silencing of calretinin decreases viability of epithelioid 
mesothelioma cells. Our aim was to elucidate mechanisms regulating calretinin 
expression in mesothelioma. Analysis of calretinin transcript and protein suggested 
a control at the mRNA level. Treatment with 5-aza-2ʹ-deoxycytidine and analysis of 
TCGA data indicated that promoter methylation is not likely to be involved. Therefore, 
we investigated CALB2 promoter by analyzing ~1kb of genomic sequence surrounding 
the transcription start site (TSS) + 1 using promoter reporter assay. Deletion analysis 
of CALB2 proximal promoter showed that sequence spanning the –161/+80bp 
region sustained transcriptional activity. Site-directed analysis identified important  
cis-regulatory elements within this –161/+80bp CALB2 promoter. EMSA and ChIP 
assays confirmed binding of NRF-1 and E2F2 to the CALB2 promoter and siRNA 
knockdown of NRF-1 led to decreased expression of calretinin. Cell synchronization 
experiment showed that calretinin expression was cell cycle regulated with a peak 
of expression at G1/S phase. This study provides the first insight in the regulation of 
CALB2 expression in mesothelioma cells.
INTRODUCTION
Malignant pleural mesothelioma (MPM) are tumors 
originating from the surface serosal cells of the pleura 
[1]. With the established standard of care, i.e. pemetrexed 
with platinum-based chemotherapy, MPM patients have a 
median survival of one year [2], therefore it is important 
to better understand the biology of mesothelioma 
development that would allow for designing and 
developing novel and more effective therapy strategies. 
Calretinin (CR, gene CALB2) is a 3̴0kDa calcium-
binding protein belonging to the EF-hand family [3]. In 
1996, Doglioni et al demonstrated specificity of calretinin 
immunoreactivity in mesothelioma compared to other 
tumor types [4]. Currently, calretinin is the most commonly 
used diagnostic mesothelioma marker [5]. Reactive 
mesothelial cells and malignant mesothelioma cells 
show nuclear and cytosolic calretinin staining allowing 
differentiation of mesothelioma from adenocarcinoma 
[6]. MPM can be categorized into three groups based on 
the histological characteristics: epithelial, biphasic and 
sarcomatoid characterized by strong, intermediate and 
weak (absent) calretinin immunoreactivity, respectively [7]. 
Three independent studies suggested that calretinin can be 
also utilized as a prognostic marker since strong calretinin 
immunostaining correlated with improved survival [7–9].
In two epithelioid mesothelioma cell lines, down-
regulation of calretinin by a lentiviral short hairpin 
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approach impaired cell proliferation and triggered 
apoptosis via the intrinsic caspase-9-dependent pathway 
[10] suggesting that calretinin is important for epithelioid 
mesothelioma cell survival. 
Calretinin is physiologically expressed in different 
neuronal cell populations, e.g. in the retina and the 
cerebellum [11] as well as in Leydig cells, Sertoli cells 
and adipocytes [5]. Little is known about the mechanisms 
regulating calretinin expression in various tissues or 
in cancer. It has been reported that the mouse Calb2 
and human CALB2 promoter region contain TATA and 
CAAT boxes [12]. A mouse Calb2 promoter fragment 
(–115/+54bp) was shown to be active in neuronal 
and cancer cells [13, 14]. In human colon cancer cells, 
calretinin expression is downregulated by butyrate, a 
substance that induces cell differentiation [15]. Butyrate–
induced calretinin downregulation is mediated through 
butyrate dependent repressive elements which are not 
operational in mesothelioma cells [16].
In this study, our aim was to investigate and 
characterize transcriptional control of calretinin expression 
in mesothelioma cells. 
RESULTS
Calretinin protein levels correlate with CALB2 
transcript levels across a panel of different 
mesothelioma cell lines
To characterize calretinin expression, we assessed 
mRNA and protein levels across a panel consisting of 
11 mesothelioma cell lines, one SV-40 immortalized 
human pleural mesothelial cell line (MeT5A) and HEK293 
cells (Figure 1A and 1B). Five cell lines were of epithelioid 
type (NCI-H226, ACC-MESO-4, ZL55, MERO-84, and 
ZL5), four were biphasic (MSTO-211H, MERO-82, 
MERO-83, SPC111) and two were sarcomatoid (ZL34 and 
ONE58). Levels of CALB2 transcript were significantly 
higher (p = 0.0285) in epithelioid histotype. Calretinin was 
also expressed in HEK293 cells, which might be expected 
since HEK293 cells are of kidney embryonic origin [17] 
and both kidney and mesothelium originate from the 
mesoderm. Importantly, CALB2 mRNA expression was 
strongly positively (p = 0.0002) correlated with calretinin 
protein levels (Figure 1C), suggesting that calretinin 
expression could be regulated either through copy number 
variation or through control of mRNA levels. 
Calretinin promoter is not inhibited by DNA 
methylation in mesothelioma cell lines and 
tumor samples
Analysis of genomic copy number abnormalities 
(CNA) in mesothelioma, using arrayMap [18] showed 
no indications of genetic alteration in CALB2 gene 
(Supplementary Figure 1) while a study has described 
loss at 16q22 in two out of 18 mesothelioma cases [19], 
indicating that upregulation of calretinin expression in 
mesothelioma is not linked to increased gene copy number. 
We then took advantage of the known differential 
expression of calretinin between epithelioid and 
sarcomatoid mesothelioma to explore whether this might 
represent a hint that calretinin expression is controlled 
by methylation of the promoter, since this mechanism 
controls the expression of several genes in MPM [20]. 
A putative CALB2 proximal promoter region was 
defined based on two criteria: the observation that most 
human promoters are found between –800 upstream 
and +200 bp downstream of putative transcription start 
site (TSS; +1) [21] and according to publicly available 
data on high throughput ChIP data reported in the UCSC 
browser (Supplementary Figure 2). In silico analysis 
(http://www.bioinformatics.org/sms2/cpg_islands.html)  
of the –838/+80bp region of CALB2 promoter using the 
method defined by Gardiner-Garden [22], documented the 
presence of CpG islands and a high GC content starting 
from 338bp upstream of the TSS. Inactivation of gene 
expression by methylation of CpG islands present in 
promoters is a common epigenetic mechanism in health 
and diseases [23]. Therefore, to test the hypothesis that 
calretinin expression might be partly driven by epigenetic 
mechanisms, ZL55 (high-calretinin, epithelioid) and 
SPC111 (low-calretinin, biphasic) cells were treated for 
seven days with the hypomethylating agent 5-aza-2ʹ-
deoxycytidine (5-Aza-CdR) at 100 and 250 nM and the 
expression of calretinin was evaluated. The expression 
of two cancer-associated testis antigens CTAG1B and 
MAGE-C1 genes was used as a positive control, since 
their promoters are known to be controlled by DNA 
methylation [24]. Although the expression of CTAG1B 
and MAGE-C1 mRNA was strongly enhanced by 5-Aza-
CdR treatment in SPC111 and ZL55 cells (Figure 2A), the 
expression of calretinin mRNA and protein (Figure 2A 
and 2B) did not increase. On the contrary, treatment 
with 5-Aza-CdR resulted in a decrease in calretinin 
protein levels, especially in SPC111 cells. Moreover, 
the methylation status of nine CpG sites in the CALB2 
promoter of epithelioid (n = 57) and biphasic (n = 23) 
mesothelioma samples from The Cancer Genome Atlas 
(TCGA) database generally showed low methylation 
levels, particularly at CpG sites nearest to the TSS 
(Figure 2C). CALB2 promoter CpG methylation was 
not significantly negatively correlated with CALB2 gene 
expression in epithelioid or biphasic tumors (Table 1). As 
control, the methylation status of MAGEC1 promoter was 
also investigated. The region of the MAGEC1 promoter 
exhibits high levels of methylation (Supplementary 
Figure 3) and the gene is lowly expressed in TCGA 
mesothelioma tumors. Importantly, several of the 
CpGs located at or near the transcriptional start site are 
significantly negatively correlated with gene expression 
(Supplementary Table 2) and the gene is lowly expressed 
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in both biphasic and epithelioid tumors. The high levels 
of DNA methylation and low levels of expression coupled 
with our experimental evidence of reactivation of gene 
expression with treatment with hypomethylating agents 
suggest that MAGEC1 serves as an appropriate control 
gene in our study. Taken together, our data suggest 
that promoter methylation is not driving differential 
expression of calretinin between mesothelioma 
histotypes.
The –161/+80bp CALB2 promoter region drives 
expression of luciferase reporter in mesothelioma 
cells 
We then investigated the activity of the CALB2 
promoter to define cis-regulatory sequences important 
for calretinin expression. Four 5ʹ-deletion promoter 
fragments (–838, –419, –264, –161bp upstream and +80bp 
downstream of TSS +1) were cloned into the firefly 
Figure 1: Differential expression of calretinin in a panel of 13 cell lines. (A) Quantitative RT-PCR analysis of CALB2 expression 
in 11 mesothelioma cell lines, one immortalized mesothelial cell line (MET5A) and HEK293 cells using histones as an internal control. 
Levels are shown relative to the HEK293 cells according to the –ΔΔCt method. (B) Western blot analysis of calretinin protein levels in the 
same panel of cell lines. Actin was used as loading control. (C) Relative mRNA levels are plotted against the relative protein levels; each 
dot represents a cell lines as in A and B. 
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luciferase basic reporter pGL3-B (Figure 3A). To test 
transcriptional activity of the promoter constructs, 
NCI-H226, Zl55, SPC111 and ONE58 cells were transiently 
transfected with the promoter constructs along with the 
pRL-TK plasmid as an internal control. The shortest 
–161/+80bp CALB2 promoter construct appeared to be 
as active as the other longer sequences in all tested cell 
lines (Figure 3B) defining this fragment as the minimal 
CALB2 promoter. The 240bp minimal promoter has more 
activity than any of the longer versions (Supplementary 
Figure 4) indicating the presence of negative regulators. 
In addition, –161/+80bp CALB2 promoter activity was 
correlated (p = 0.017) with CALB2 expression (Figure 3C) 
with the lowest transcriptional activity observed in ONE58 
cells which express extremely low levels of calretinin, 
and the highest transcriptional activity in NCI-H226 
cells, expressing the highest levels of calretinin. Since 
the –161/+80bp fragment was sufficient to drive reporter 
expression in the tested mesothelioma cells, the next step 
was to further characterize its cis-regulatory elements.
Mutation of E2F2/NRF-1-like site strongly 
reduced promoter activity 
To search for putative protein binding sites, in silico 
analysis was performed on the sequence from –161bp 
to +80bp of the CALB2 promoter using MatInspector 
software [25]. Most frequently identified binding sites 
were the ones for NRF-1 (nuclear respiratory factor 1), 
as well as for E2F family members and CREB (cAMP 
Figure 2: Promoter methylation does not regulate calretinin expression in cell lines and tumor samples. (A) ZL55 and 
SPC111 cells were treated for 7 days with the hypomethylating agent 5-Aza-CdR (100 nM and 250 nM). Analysis of mRNA showed no 
change in CALB2 expression but strong upregulation of MAGE-C1 and CTAG1B expression. Mean ± SD, n = 3. (B) Calretinin protein 
levels decreased upon 5-Aza-CdR treatment in both ZL55 and SPC111 cells. Representative of three independent experiments. (C) CpG 
sites in the promoter region of CALB2 from the Illumina HumanMethylation450 array are shown in 5ʹ to 3ʹ order versus methylation beta-
value which represents the percent methylation of the sample. Mesotheliomas are stratified by tumor histology, epithelioid (n = 57), and 
biphasic (n = 23). 
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response element binding protein) (Figure 4A). The 
activation of the latter has been observed in vitro after 
exposure of mesothelial cells to asbestos [26]. Promoter 
constructs containing selective mutations were created 
using a site-directed mutagenesis approach (Figure 4B) 
and their transcriptional activity was measured in ZL55 
and SPC111 cells. All mutated promoter constructs 
showed significantly decreased transcriptional activity 
compared to the control construct in both cell lines 
(Figure 4C). The transcriptional activity of the E2F2/NRF-
1 (–64)-like mutant resulted in a 80% decrease compared 
to the wild-type promoter sequence suggesting that E2F2 
or NRF-1 might be important for the transcriptional 
control of calretinin expression. A strongly reduced 
activity of the E2F2/NRF-1 mutant construct was also 
observed in HEK293 cells (Supplementary Figure 5), 
indicating that this transcriptional control is not restricted 
to mesothelioma cells, but possibly to other cells of 
mesodermal origin.
In vitro and in situ binding of NRF-1 and E2F2 
to E2F2/NRF-1-like binding motif in the CALB2 
promoter
Alignment of the CALB2 promoter ortholog 
nucleotide sequences (Supplementary Figure 6) revealed 
that the stretch containing the putative binding sites for 
E2F2 or NRF-1 (–75 to –51bp) shows the highest degree 
of identity across various species (Figure 5A). Therefore, 
to experimentally demonstrate potential functionally 
relevant binding of E2F2 or NRF-1, an EMSA assay was 
performed using biotin labeled 25-bp oligonucleotide 
containing the putative E2F2/NRF-1 binding site 
(Figure 5B). Upon incubation of ZL55 nuclear extract 
with the specific labeled probe, DNA-protein complexes 
C1, C2 and C3 were formed (Figure 5B, lane 2). All three 
DNA-protein complexes were diminished with increasing 
amounts of unlabeled competitor (Figure 5B, lane 3 
and 4) but were not outcompeted using an unrelated oligo 
competitor (data not shown). However, in the reaction with 
mutated competitor, the C3 complex was detected again 
but not the complexes C1 and C2 (Figure 5B, lane 5). 
Addition of a specific antibody against NRF-1 resulted in 
the appearance of a heavier complex (Figure 5B, lane 6) 
and a decrease of the C2 complex, while no change was 
observed with an anti-E2F2 antibody (Figure 5B, lane 7). 
To confirm in situ in cultured cells the presence 
of NRF-1 or E2F2 on the CALB2 promoter, chromatin 
immunoprecipitation assay (ChIP) was performed in 
ZL55 cells with antibodies against NRF-1 and E2F2. 
The promoter of CDC25A gene, a known E2F target 
[27] lacking a binding site for NRF-1, was used as a 
negative control for NRF-1 and as a positive control for 
E2F2. Chromatin immunoprecipitation assay showed 
that compared to CDC25A, NRF-1 was significantly 
enriched in CALB2 promoter whereas E2F2 bound to 
both, CDC25A and CALB2 promoters (Figure 5C). These 
data demonstrate that NRF-1 and E2F2 are able to bind to 
CALB2 promoter. 
NRF-1 expression levels are likely not responsible 
for differences in calretinin expression levels observed in 
the various MPM lines since NRF-1 levels were rather 
homogenous in the tested cell lines (Figure 5D). However, 
silencing of NRF-1 resulted in calretinin downregulation 
in SPC111 cells (Figure 5E and Supplementary Figure 7). 
Taken together, these data provide evidence that NRF-1 is 
an important positive regulator for calretinin expression.
Calretinin expression is cell cycle-dependent
Besides NRF-1, members of the E2F family were 
among the most frequently identified putative transcription 
factors binding to the –161/+80bp CALB2 promoter 
Table 1: Correlation between CALB2 gene promoter CpG methylation and CALB2 expression 
(*Spearman’s test)
cgID Chromosome Position Epithelioid Correlation Epithelioid P-value*
Biphasic 
Correlation
Biphasic 
P-value*
cg27304754 16 71392088 0.12 0.385 0.45 0.034
cg16893574 16 71392095 –0.14 0.296 0.42 0.047
cg09213102 16 71392373 –0.14 0.312 0.35 0.122
cg07108002 16 71392377 –0.24 0.068 0.23 0.285
cg04245373 16 71392615 0.02 0.893 –0.26 0.223
cg06493664 16 71392628 0.04 0.749 –0.41 0.053
cg09697458 16 71392748 –0.09 0.502 0.05 0.823
cg09452293 16 71392838 –0.16 0.230 0.05 0.823
cg27207776 16 71393801 –0.25 0.063 –0.07 0.740
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region and E2F2 binding was detected by ChIP analysis. 
Since E2F family members regulate cell cycle-dependent 
expression of many genes [28], we hypothesized that 
calretinin expression might be regulated in a cell cycle-
dependent manner. To investigate the kinetics of calretinin 
expression, ZL55 and SPC111 cell were exposed to double 
thymidine treatment followed by nocodazole treatment, 
after which calretinin expression was assessed at different 
time points (Figure 6A and 6B). The progression through 
the cell cycle was monitored by flow cytometry analysis 
(data not shown), while the expression pattern of cyclin A 
and cyclin E (Figure 6A) served to document the transition 
of cells from G1/S to M phase [29, 30]. Double thymidine 
treatment synchronized the majority of cells at the G1/S 
transition, where high levels of calretinin expression 
were observed (Figure 6A). Calretinin expression then 
significantly decreased 5 h after thymidine removal when 
the majority of cells were in the G2/M phase. The same 
Figure 3: Transcriptional activity of the minimal CALB2 promoter is proportional to calretinin expression. Transcriptional 
activity of different promoter constructs was assessed by transient transfection and dual luciferase assay using pTK-RL as an internal 
control. (A) 5ʹ-deletion constructs of the CALB2 promoter engineered in the pGL3-basic (pGL3-B) luciferase reporter plasmid. Lines 
represent CALB2 promoter fragment; the name and the size are indicated by nucleotide position upstream (–) or downstream (+) relative 
to the transcription start site (+1). (B) CALB2 promoter activity in ONE58, SPC111, ZL55 and NCI-H226 cells, which express different 
levels of calretinin. To allow for comparison of the absolute promoter activity between the cell lines, Firefly light units were multiplied 
by a correction factor that compensates for differences in the transfection efficacy. The correction factor was based upon the Renilla Light 
Units (ReLU) of the internal control, pTK-RL, and was calculated by dividing the mean ONE58 ReLU by the mean of ZL55, SPC111 and 
H226 ReLU for each construct. Mean ± SD, n = 3. (C) Relative mRNA abundance is plotted versus the relative Firefly light units reflecting 
absolute –161/+80bp CALB2 activity for the indicated cell lines. 
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Figure 4: Effect of site-directed mutagenesis of transcription factor binding sites on the –161/+80bp CALB2 promoter 
activity. (A) Predicted potential TF binding sites (highly conserved nucleotides selected for site-directed mutagenesis are colored in red). 
(B) A series of mutant constructs harboring mutated nucleotides (in red) of predicted E2F2, NRF-1 and CREB binding sites. Numbers 
indicate the position of the first (from the left to the right) mutated nucleotide. (C) The wild-type reporter plasmid expression was arbitrarily 
set to 100% and the reporter activity of the mutants was expressed as a percentage of the wild-type construct. Mean ± SD n = 3; *p < 0.05; 
**p < 0.01; ***p < 0.005.
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kinetics of transient and cell cycle-dependent calretinin 
expression was observed by immunofluorescence 
(Figure 6B), suggesting that calretinin expression is cell 
cycle- dependent, being upregulated in G1/S phase of the 
cell cycle. 
DISCUSSION
In the present study we found cis-regulatory 
sequence elements that are essential for calretinin 
expression in mesothelioma cells, and identified NRF-1/
E2F2 as transcription factors binding to this regulatory 
sequence. 
Mechanisms regulating calretinin expression 
have been investigated in neuronal cells and colon 
adenocarcinoma cells, whereas in mesothelioma cells 
they have not been thoroughly explored yet. A 1.5 kb 
stretch of the mouse Calb2 promoter (–1485/+60bp) was 
demonstrated to drive reporter expression in cultured 
neuronal cell derived from primary embryonic mouse brain 
tissue [12]. Additionally, a bipartite butyrate-responsive 
element in the human CALB2 promoter was found to act 
as a repressor element upon butyrate treatment in colon 
carcinoma but not in mesothelioma cells [16]. However, 
specific cis-regulatory elements positively regulating 
calretinin expression had not yet been identified.
Figure 5: NRF-1 and E2F2 bind to the CALB2 promoter. (A) Nucleotide sequence comparison reveals high homology in the 
CALB2 promoter regions of different species in the stretch containing E2F2/NRF-1 predicted binding sites. The analysis was performed 
using the ClustalW2 software. Asterisks indicate conserved nucleotides. (B) EMSA assay showing that a 25bp-oligo containing E2F2/NRF-
1-like sites forms three DNA-protein complexes (C1, C2, C3) when incubated in with the ZL55 cells-derived nuclear extracts. Addition of 
a NRF-1 antibody but not of one against E2F2 resulted in a supershift (SS). (C) qPCR analysis on CDC25A and CALB2 promoter regions 
after ChIP-experiments. Data of two independent experiments were normalized to input. (D) NRF-1 protein expression in different cell 
lines. Actin is used as loading control. (E) NRF-1 silencing resulted in downregulation of calretinin expression.
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Genomic sequence surrounding transcription start 
site of CALB2 gene contains a GC-rich region indicating 
a possible role for DNA methylation in regulating 
calretinin expression. However, 5-Aza-CdR, a DNA 
hypomethylating agent, did not increase calretinin 
expression in low-calretinin expressing SPC111 cells. It 
even resulted in a decrease in calretinin expression levels 
indicating that a certain degree of methylation is required 
for optimal/maximal CALB2 transcription. Additionally, 
we did not observe differential methylation status of 
CALB2 promoter between epithelioid and biphasic 
mesothelioma in tumors from TCGA database or a strong 
negative correlation of promoter methylation with gene 
expression. Thus altered DNA methylation of the CALB2 
promoter is very likely not responsible for the differences 
in calretinin expression levels between low-expressing 
biphasic/sarcomatoid and high-expressing epithelioid 
mesothelioma cells. 
We further characterized a stretch of ̴1 kb 
(–835/+80bp) of the human CALB2 promoter by 
creating four different 5ʹ-deletion promoter reporter 
constructs and testing their activity in four different 
mesothelioma cell lines. The –161/+80bp fragment 
of the CALB2 promoter was identified as the minimal 
element resulting in sustained transcriptional activity in 
all tested mesothelioma cell lines. This is consistent with 
the previously defined minimal mouse Calb2 promoter 
(–115/+54bp) shown to be active in rat cortical neuronal 
cells, rat cerebellar granule cells, colon adenocarcinoma 
(WiDr) and mesothelioma cells (SPC111) [13, 14]. 
Moreover, we found that the transcriptional activity of 
the –161/+80bp CALB2 promoter reporter was highly 
correlated with CALB2 expression levels. We are aware 
that using as normalizer pRL-TK plasmid, which carries 
the Renilla luciferase gene under the HSV-1 TK promoter 
might theoretically be affected by different levels of 
Figure 6: Cell cycle-dependent regulation of calretinin expression. (A) Calretinin levels in protein lysates from ZL55 and 
SPC111 synchronized cells collected at different time points (0 h, 3 h, 5 h, 7 h, 24 h) after removal of thymidine block. Analysis of cyclin 
A and cyclin E expression was used as a reference for cell cycle progression. A nuclear extract of HeLa cells is used to identify the position 
of the bands of cyclin A and cyclin E Due to the considerably different calretinin expression levels of ZL55 and SPC111 cells, two different 
exposure times are presented. (B) Immunofluorescence analysis of SPC111 cells using calretinin antibody (green) at the same time points 
as in (A) Cells nuclei are stained with DAPI (blue), and calretinin immunofluorescence is shown in green.
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Specificity protein 1 (Sp1) [31]. Rao et al reported recently 
overexpression of Sp1 in mesothelioma compared to 
normal mesothelium [32]. However, the variation of 
Sp1 levels between the lowest and the highest expressing 
mesothelioma cell line investigated was 4-fold. Since we 
observed an about 30-fold difference in CALB2 promoter 
activity between the different mesothelioma cell lines, we 
can reasonably assume that the difference is not due to 
differential expression of the normalizer. 
In silico analysis of the human –161/+80bp 
CALB2 minimal promoter region revealed a series of 
potential functional transcription factors (TF) among 
which NRF-1, E2F2 and CREB were of greatest interest 
for the following reasons. NRF-1 is a transcription factor 
implicated in mitochondrial biogenesis and function [33] 
and was predicted as TF binding to the CALB2 promoter 
[34]. Computer-assisted identification predicted CALB2 
to be an E2F target gene as well [35]. Finally, CREB 
had been demonstrated as an asbestos activated TF in 
human mesothelial cells [26]. Mutation of E2F2 (–69), 
NRF-1 (–41), two NRF-1 (–41;–35) and CREB (–2) 
predicted binding sites significantly reduced CALB2 
promoter activity in ZL55 and SPC111 cells. Mutations 
in the E2F2/NRF-1 (-64;-63;-61) putative binding sites 
(GAGCGCGCGCGCCCCCT; bold indicates NRF-1 
consensus, underlined are the nucleotides mutated in the 
functional assay) led to a 70–80% decrease in the promoter 
activity revealing this sequence as the most important cis-
acting site. In the studies of Billing-Marczak et al [13, 14], 
an essential element for the promoter activity in the mouse 
Calb2 promoter (–115/+54bp) was located at the –91/–
80bp position and identified as an “AP-2 like” sequence 
(CGCCCCCTTCCG, in bold are nucleotides overlapping 
with NRF-1 consensus, underlined are the nucleotides that 
had been mutated in the functional assay). Although trans-
acting factors were not identified, functional inactivation 
in neuronal cells was obtained by mutating one nucleotide 
also present in the E2F2/NRF-1 putative binding site. The 
same mutation did not abolish promoter activity in cancer 
cells [14]. This could be interpreted in two ways: either 
mutating a single base in the E2F2/NRF-1 binding site is 
not enough to abolish activity in cancer cells or different 
transcription factors are operational in neuronal and cancer 
cells. 
A nucleotide sequence analysis revealed that the 
E2F2/NRF-1-site in the CALB2 promoter region displays a 
high degree of identity across different species. An EMSA 
assay revealed three different DNA-protein complexes and 
chromatin immunoprecipitation assay showed the presence 
of both NRF-1 and E2F2 bound to CALB2 promoter. This 
is consistent with a previous study demonstrating that 
NRF-1 is a co-regulator of E2F family members target 
genes [27]. For all these reasons and since we observed 
similar expression of NRF-1 in a panel of mesothelioma 
cell lines with different calretinin expression levels, it 
is most likely that NRF-1 is a part of a protein complex 
that altogether activates calretinin expression. Identified 
proteins interacting with NRF-1 include SP4 (specificity 
protein 4) [36]. Interestingly, the in silico analysis on 
–160/+80bp CALB2 promoter region predicted a SP4 
binding site located next to the E2F2/NRF-1 site. SP4 
expression is tissue specific, primarily expressed in the 
brain, some epithelial tissues, testis and developing teeth 
[37] and its coordinate activity with NRF-1 has been 
described to couple energy generation and neuronal 
activity [38]. Further studies should investigate whether 
SP4 is involved in the regulation of calretinin expression.
E2F factors are known to regulate S-phase entry 
[39]. Consistent with E2F regulating CALB2 promoter 
activity, calretinin expression was found to be cell 
cycle-dependent with a maximum level of expression 
at G1, and progressively decreased during cell cycle 
progression. Since calretinin expression is associated with 
better clinical outcome [7–9], it would be interesting to 
investigate whether tumor cells positive for calretinin are 
growth arrested cells. 
Knowledge about mechanisms regulating NRF-1 
and E2F would help for a better understanding of 
the complex biology of mesothelioma, where loss of 
calretinin expression during epithelioid tumor progression 
is associated with worst outcome (Vrugt et al, ms in 
preparation).
Investigation of the promoter of another MPM 
marker, mesothelin, has led to the discovery of a cancer-
specific element driving mesothelin overexpression in 
cancers [40]. In the transgenic MexTAg mouse model, 
where the mesothelin promoter is placed upstream of 
the large T antigen, the promoter becomes active in 
mesothelial cells after asbestos exposure, leading to 
asbestos induced mesothelioma [41]. This suggests that 
different transcription factors act on the mesothelin 
promoter in normal cells and cancer cells. In several 
studies aiming at driving suicide gene expression in 
cancer cells, a 2.2kb human CALB2 promoter fragment 
was reported not to be specific for cancer cells [42, 43]. 
In our study, we describe a CALB2 promoter fragment 
(–161/+80bp) with activity proportional to calretinin 
expression and identified NRF-1/E2F2 as specific trans-
activating factors. Future studies will assess whether this 
promoter activity is differently regulated in cancer and 
neuronal cells.
Although this work cannot directly exclude a role 
of post-transcriptional mechanisms such as RNA stability 
in regulating calretinin expression in mesothelioma cells, 
this is the first study defining trans-activating factors in a 
gene that is not only a diagnostic and prognostic marker, 
but also has a functional role in MPM. Our experiments 
demonstrate that calretinin expression is activated at the 
transcriptional level by NRF-1 and E2F2 transcription 
factors and that expression levels are cell cycle-dependent. 
Given recent findings about E2Fs involvement in processes 
such as regulation of cell fate, occasionally linked to 
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metabolic adaptation [44], our results on the regulation 
of calretinin expression are expected to have a persistent 
impact for the understanding of MPM development. 
MATERIALS AND METHODS
Cell culture
The following mesothelioma cell lines have been 
used: ZL55, ZL5, ZL34 and SPC111 from our laboratory 
[45]; NCI-H226, MSTO-211H, MeT5A [46] were 
obtained from ATCC; ACC-MESO-4 [47] were obtained 
from Riken BRC; and MERO-82, MERO-83, MERO-84 
[48] and ONE58 [49] were obtained from the European 
Collection of Cell Cultures. MPM cells established in our 
laboratory were maintained as described by Thurneysen 
et al [50] and were authenticated by DNA fingerprinting 
of short tandem repeat loci (Microsynth, Switzerland). 
The other cell lines were cultured in D-MEM-F12 
supplemented with 15% FCS and 1% Penicillin/
Streptomycin solution. HEK293 cells were cultured in 
DMEM high glucose medium supplemented with 10% 
FCS and 1% penicillin/streptomycin. All cells were 
cultured at 37°C in a humidified 5% CO2 atmosphere.
Gene expression analysis
RNA extraction using Qiagen RNAeasy® and 
cDNAs was prepared from 400–500 ng of total RNA 
(Qiagen QuantiTect® Reverse Transcription protocol) 
[51]. Selected gene expression analysis using MIQE [52] 
compliant protocols was conducted as previously described 
[51]. Briefly, cDNA was amplified by the SYBR-Green 
PCR assay and products were detected on a 7900HT Fast 
real-Time PCR system (SDS, ABI/Perkin Elmer). Relative 
mRNA levels were determined by comparing the PCR 
cycle thresholds between cDNA of a specific gene and 
histone (ΔCt method). The following primers were used: 
calretinin (5ʹ-GCGAACCGGCCGTACGATGA-3ʹ and 
5ʹ-AGAGGCCCAATTTGCCATCCCCG-3), Mage-C1 
(5ʹ-GGGATGTGCTGAGTGGAATAG-3ʹ and 5ʹ-CTCCC 
GGTACTCTAGGTAATGT-3ʹ), CTAG1B (NY-ESO-1) 
(5ʹ-GTCCGGCAACATACTGACTATC-3ʹ and 5ʹ-GTGA 
TCCACATCAACAGGGAA-3ʹ).
Western blot analysis
Total protein extracts were prepared by lysing 
the cells with hot Laemmli sample buffer (60 mM Tris-
Cl pH 6.8, 100 mM DTT, 5% glycerol, 1, 7% SDS) 
and pressed few times through syringes (26 G). Protein 
concentration was determined using a Pierce™ 660nm 
Protein Assay (Thermo Scientific). A total of 5 µg 
protein per extract was separated on denaturing 10–20% 
gradient SDS-PAGE gels. Proteins were transferred on 
PVDF transfer membranes (0.45 µm, Perkin Elmer). 
For Western blotting, membranes were probed with the 
following primary antibodies: anti-calretinin (Sigma, 
HPA007306), anti-cyclin E (Santa Cruz Sc-247), anti-
cyclin A (Millipore, 06–138), anti-NRF-1 (Santa Cruz 
SC33771, H300) and mouse anti-actin (#69100) from MP 
Biomedicals. Membranes were then incubated with the 
secondary antibody rabbit anti-mouse IgG-HRP (A-5420) 
from Antell, and goat anti-rabbit IgG-HRP (#7074) from 
Cell Signaling. The signals were detected by enhanced 
chemiluminescence (ECL™ Western Blotting Reagents, 
GE Healthcare) and detected on photosensitive film (Super 
RX Fuji x-Ray Film, Fujifilm). Relative quantification was 
assessed using ImageJ (NIH).
5-aza-2ʹdeoxycytidine treatment of cells
On the first day, 2.5 × 104 cells were seeded in a 
6-well plate and on the next day the medium was replaced 
with the medium containing 100 nM and 250 nM of 
5-Aza-2-CdR. After 24 h, the drug containing medium 
was replaced with the fresh medium. On the fifth day, 
cells were treated again with 5-Aza-2CdR for 24 h and 
then the medium was replaced by fresh one. Cells were 
kept in culture for another 24 h after which samples were 
collected for RT-PCR and Western blot analysis.
In silico analysis
Analysis of the 241bp of the promoter sequence for 
potential functional transcription factors was carried out 
using MatInspector software (Genomatix Software GmbH, 
Munich, Germany) [25]. 
Level 3 normalized DNA methylation data and 
clinical information was downloaded from The Cancer 
Genome Atlas (TCGA) data portal on August 10th, 2015. 
Normalized CALB2 gene expression values (RNAseq) 
from the same TCGA samples were downloaded from 
the UCSC cancer genome browser on August 10th, 2015. 
There were 87 mesotheliomas with available Illumina 
HumanMethylation450 methylation, gene expression, 
and clinical data. The majority of tumors were epithelioid 
histology (n = 57), with n = 23 biphasic, n = 5 diffuse not 
otherwise specified and n = 2 sarcomatoid tumors. Patient 
demographic and tumor characteristics are provided in 
Supplementary Table 1. 
Plasmids constructs and side-directed 
mutagenesis
To investigate the control of CALB2 transcription, 
838bp, 419bp, 216bp and 161bp upstream and 80bp 
downstream of the CALB2 transcription starting 
site were amplified from genomic DNA ZL55 cells 
using following primers: F: 5ʹ-ACGT NheIGCTAGC 
–838ACATTCCCACGATGTCCCTA-3ʹ (Addgene, 66750); 
F: 5ʹ- ACGTNheIGCTAGC-419AGCTCTTCCTGCTGTGGA 
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AGGATCAGAA-3ʹ (Addgene, 66747); F: 5ʹ-ACGTNheIGC 
TAGC –264AAGTGGTGGATGTACTCAAG-3ʹ (Addgene, 
66746); F:5ʹ- ACGT HindIIIAAGCTT –161TCTCAGCGCA 
GAGGTAAGGG-3ʹ (Addgene 66745)- along with the 
reverse primer: R: 5ʹ-ACGT HindIIIAAGCTT +155CC 
ATATTTCCAGGAACTGGGACGCCGTC-3ʹ. In order to 
avoid ORF shifts due to the start codon of CALB2 gene but 
still to include the 5ʹ-UTR, NcoI restriction sites in 3’ site 
of the PCR product along with the restriction site within 
the forward primer (5ʹ) were used to subclone amplicons 
into the pGL3-basic vector. To obtain constructs with 
specific mutations, the QuikChange II Site-Directed 
Mutagenesis kit (Stratagene) was used (mtE2F (–69)-, 
Addgene 66743; mtCREB (–2), Addgene 66751; mtNRF-1 
(–41), Addgene 66744, dmtNRF-1 (–41;–35)-, Addgene 
66741, E2F2/NRF-1 (–64), Addgene 66742). 
Transient transfections and reporter assays 
To investigate CALB2 transcription, the dual 
luciferase assay was used. Briefly, the different constructs 
were transfected together with Renilla Luciferase (50:1) in 
cells seeded in 12 wells (100’000 cells/well) as previously 
described [53]. After 48 h, cells were lysed and analyzed 
using Dual-Luciferase reporter assay system according to 
manufacturer’s instruction (Promega, Madison, Wi, USA).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagent (Pierce) 
following the manufacturer’s protocol. The binding 
reaction was performed by incubating 5 µg of nuclear 
extract with 125fmol biotin labelled oligonucleotide 
(5ʹ-CCCTGAGCGCGCGCGCCCCCTTCTG-3ʹ) in the 
presence of 10mM Tis-HCl pH8.0, 25 mM NaCl, 10 mM 
DTT, 5% glycerol, 10 mM MgCl, 2 µM ZnCl, 1 µg salmon 
sperm dsDNA, 1%NP-40 and incubated on ice for 50 min. 
For competition reactions, the nuclear extracts were 
incubated with the specific unlabelled oligonucleotides for 
10 min prior to addition of biotin-labelled oligonucleotides 
and incubated 40 min on ice. For the supershift 
experiments, specific antibodies (NRF-1 ab34682 and 
E2F2 sc699 ×) were added after 30min incubation of the 
nuclear extracts and biotin-labeled probes and incubated 
another 20 min on ice. The samples were separated on 
a 6% 0.5 × TBE gel, transferred on a nylon membrane 
and visualized using the Chemiluminescent Nucleic Acid 
Detection Module (89880) according to the manufacturer’s 
protocol.
Chromatin immunoprecipitation (ChIP)
ChIP was carried out according to the protocol 
previously described [54]. In brief, cultured cells (4 × 106) 
were treated with 1% formaldehyde to crosslink proteins 
to DNA. Chromatin was sonicated using a Bioruptor 
ultrasonic cell disruptor (Diagenode) to shear genomic 
DNA to fragments between 100bp and 200bp. Chromatin 
(20 μg) was diluted tenfold with immunoprecipitation 
buffer (16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl, 
1.2 mM EDTA, 0.01% SDS and 1.1% Triton X-100) 
and then immunoprecipitated overnight with the 
corresponding antibodies (NRF-1 Abcam ab34682 and 
E2F2 Santa Cruz sc699X). After washing, elution and 
de-crosslinking, the precipitated DNA was purified with 
phenol-chloroform, ethanol precipitated and quantified 
by quantitative PCR. Following primers were used: 
CDC25A (5ʹ-TTTCGCGGTAATAGCGGCTC-3ʹ and 
5ʹ-TAGCTGCCATTCGGTTGAGAG-3ʹ) and CALB2 
(5ʹ-AGGTAAGGGCCCTCTAGGAGT-3ʹ and 5ʹ-CTGCCC 
TTATATACGCTCTGGA-3ʹ).
RNA interference by siRNA
For the down-regulation of NRF-1 with small 
interfering RNAs (siRNA), SPC111 cells were transfected 
with 25 nM Qiagen smartpool or individual siRNAs 
targeting NRF-1 or control non targeting (NT) siRNA 
(Thermo Scientific Dharmacon), according to the 
manufacturer’s reverse transfection protocol as previously 
described [53]. 3 × 104 cells were then plated in and whole 
cell lysate was prepared after 72 h.
Cell synchronization
Cells were synchronized at the G1/S and G2/M 
border using a thymidine double-block/nocodazole 
release protocol [55]. Briefly, cells were seeded in 6-well 
(5 × 104 cells/well) then 24 h later were treated with 2 mM 
thymidine for 12 h and released for 12 h in fresh medium 
before the second block was performed for another 12 h 
with 2 mM thymidine. Cells were then washed three times 
in phosphate buffer saline (PBS) and either collected 
(hours after treatment = 0) or released in fresh medium 
containing 40 ng/ml nocodazole to induce mitotic arrest 
(G2/M) for different time periods. 
Immunofluorescence
SPC111 cells were grown on 12-mm glass coverslips 
in 24-well plates. Using the same synchronization protocol 
described above, asynchronized and synchronized 
cells were fixed for 10 min with 4% paraformaldehyde 
and permeabilized with 0.05% saponin for 5 min. The 
cells were then incubated over night at 4 C with an 
anti-calretinin antibody diluted in PBS containing 1% 
bovine serum albumin. Secondary antibodies, Alexa Fluor 
488- conjugated goat anti-rabbit IgG (Life Technologies) 
antibody was added for 1 h at RT. Nuclear DNA was 
stained using DAPI. Coverslips were mounted using 
Prolong Gold antifade reagent (Life Technologies). Images 
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were acquired using an Olympus B × 61 microscope 
(Schwerzenbach, Switzerland) equipped with an F-view 
camera for conventional fluorescence imaging. The image 
capture was controlled with the AnalySISPro software 
(Soft Imaging System, Münster, Germany). 
Statistics
Data are expressed as mean ± standard deviation of 
multiple experiments. Statistical analysis was performed 
using Mann-Whitney tests using StatView 5.0.1 (SAS 
institute). Spearman’s correlation tests were used to 
compare TCGA promoter methylation versus gene 
expression levels. Differences were considered statistically 
significant at p < 0.05.
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